MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Amgen Inc

Suletud

SektorTervishoid

306.57 -1.53

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

304.93

Max

312.17

Põhinäitajad

By Trading Economics

Sissetulek

-2.2B

627M

Müük

586M

9.1B

P/E

Sektori keskmine

41.156

63.778

Aktsiakasum

5.31

Dividenditootlus

3.06

Kasumimarginaal

6.901

Töötajad

28,000

EBITDA

-517M

2.9B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+6.7% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.06%

2.39%

Järgmine tulemuste avaldamine

1. mai 2025

Järgmine dividendimakse kuupäev

6. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. mai 2025

Turustatistika

By TradingEconomics

Turukapital

14B

167B

Eelmine avamishind

308.1

Eelmine sulgemishind

306.57

Uudiste sentiment

By Acuity

52%

48%

302 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. veebr 2025, 21:29 UTC

Tulu

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30. okt 2024, 20:18 UTC

Tulu

Amgen Posts Higher 3Q Sales on Strong Demand

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. veebr 2025, 21:02 UTC

Tulu

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Adj EPS $5.31 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Rev $9.1B >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q EPS $1.16 >AMGN

4. veebr 2025, 21:01 UTC

Tulu

Amgen 4Q Net $627M >AMGN

28. jaan 2025, 10:30 UTC

Peamised uudised

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27. dets 2024, 07:00 UTC

Tulu

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23. dets 2024, 15:04 UTC

Peamised uudised

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13. dets 2024, 14:53 UTC

Peamised uudised

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30. nov 2024, 12:00 UTC

Peamised uudised

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26. nov 2024, 12:34 UTC

Peamised uudised

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4. nov 2024, 12:00 UTC

Peamised uudised

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30. okt 2024, 20:02 UTC

Tulu

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30. okt 2024, 20:01 UTC

Tulu

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30. okt 2024, 20:01 UTC

Tulu

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30. okt 2024, 20:01 UTC

Tulu

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

6.7% tõus

12 kuu keskmine prognoos

Keskmine 332.43 USD  6.7%

Kõrge 389 USD

Madal 280 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

11

Osta

6

Hoia

1

Müü

Tehniline skoor

By Trading Central

304.35 / 318.66Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

302 / 386 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.